Back to top
more

Arena Pharmaceuticals, Inc. (ARNA)

(Delayed Data from NSDQ)

$47.60 USD

47.60
308,048

+1.62 (3.52%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?

Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.

    What's in Store for Puma (PBYI) this Earnings Season?

    Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.

      What's in Store for Arena (ARNA) this Earnings Season?

      Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.

        Mylan (MYL) to Report Q2 Earnings: What's in the Cards?

        Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.

          Can CVS Health (CVS) Pull a Surprise this Earnings Season?

          CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.

            What's in the Cards for Celldex (CLDX) this Earnings Season?

            With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

              Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?

              ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.

                Repros (RPRX) Q2 Earnings: What's in Store for the Stock?

                Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.

                  Can Ligand (LGND) Pull a Surprise This Earnings Season?

                  Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

                    GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?

                    Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.

                      Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?

                      Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.

                        What's in the Cards for Adverum (ADVM) this Earnings Season?

                        Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                          What's in the Cards for Merrimack (MACK) in Q2 Earnings?

                          Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.

                            AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study

                            AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.

                              What's in the Cards for Geron (GERN) this Earnings Season?

                              Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

                                Top Ranked Momentum Stocks to Buy for July 24th

                                Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:

                                  Arena Announces Secondary Stock Worth $150M (revised)

                                  Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

                                    Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge

                                    Arena Pharmaceuticals (ARNA) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                      Top Ranked Momentum Stocks to Buy for July 14th

                                      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 14th:

                                        Company News for July 12, 2017

                                        Companies in the News are: FOLD,SLP,ARNA,EVGN,MON

                                          Arena Announces Secondary Stock Offering of 150M Shares

                                          Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.

                                            Madeleine Johnson headshot

                                            Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today

                                            On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.

                                              Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

                                              Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

                                                Are Options Traders Betting on a Big Move in Arena Pharmaceuticals (ARNA) Stock?

                                                Investors in Arena Pharmaceuticals, Inc. (ARNA) need to pay close attention to the stock based on moves in the options market lately.

                                                  Arena Ends Study on Extended Release Formulation of PAH Drug

                                                  Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.